This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Not applicable	<p>An SAR study characterized a series of aryl <i>bis</i>(diazoniumdiolate) nitric oxide (NO) prodrugs with antiproliferative activity that could be useful for treating cancer. In a variety of cancer cells, the compounds, which contain two NO-releasing moieties, generated higher levels of NO and were better inhibitors of cell proliferation compared with the parent compound, O²-[2,4-dinitro-5-[4-(<i>N</i>-methylamino) benzoyloxy]phenyl] 1-(<i>N,N</i>-dimethylamino)diazene-1-ium-1,2-diolate (PABA/NO). Next steps include animal testing to determine the pharmacokinetic and toxicity profiles of the compounds.</p> <p>SciBX 2(2); doi:10.1038/scibx.2009.46 Published online Jan. 15, 2009</p>	<p>Patented; available for licensing from the NIH Office of Technology Transfer Contact: Steve Standley, NIH Office of Technology Transfer e-mail: sstand@mail.nih.gov</p>	<p>Andrei, D. <i>et al. J. Med. Chem.</i>; published online Nov. 18, 2008; doi:10.1021/jm800831y Contact: Larry K. Keefer, National Cancer Institute at Frederick, Frederick, Md. e-mail: keefer@ncifcrf.gov Contact: Daniela Andrei, Dominican University, River Forest, Ill. e-mail: dandrei@dom.edu</p>